

Susan E Yount

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8588994/publications.pdf>

Version: 2024-02-01

51
papers

6,294
citations

279701

23
h-index

206029

48
g-index

52
all docs

52
docs citations

52
times ranked

8580
citing authors

#	ARTICLE	IF	CITATIONS
1	The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008. <i>Journal of Clinical Epidemiology</i> , 2010, 63, 1179-1194.	2.4	3,521
2	Evaluation of Item Candidates. <i>Medical Care</i> , 2007, 45, S12-S21.	1.1	632
3	PROMIS® Adult Health Profiles: Efficient Short-Form Measures of Seven Health Domains. <i>Value in Health</i> , 2019, 22, 537-544.	0.1	335
4	Clinical validity of PROMIS Depression, Anxiety, and Anger across diverse clinical samples. <i>Journal of Clinical Epidemiology</i> , 2016, 73, 119-127.	2.4	323
5	Relative to the general US population, chronic diseases are associated with poorer health-related quality of life as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS). <i>Journal of Clinical Epidemiology</i> , 2010, 63, 1195-1204.	2.4	299
6	What Are the Most Important Symptom Targets When Treating Advanced Cancer? A Survey of Providers in the National Comprehensive Cancer Network (NCCN). <i>Cancer Investigation</i> , 2003, 21, 526-535.	0.6	94
7	Health-Related Quality of Life in Patients with Idiopathic Pulmonary Fibrosis. <i>Lung</i> , 2016, 194, 227-234.	1.4	82
8	Assessment of Patient-Reported Clinical Outcome in Pancreatic and Other Hepatobiliary Cancers. <i>Journal of Pain and Symptom Management</i> , 2002, 24, 32-44.	0.6	80
9	Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). <i>The Journal of Supportive Oncology</i> , 2006, 4, 191-9.	2.3	65
10	A Randomized Trial of Weekly Symptom Telemonitoring in Advanced Lung Cancer. <i>Journal of Pain and Symptom Management</i> , 2014, 47, 973-989.	0.6	64
11	Clinical factors associated with worse quality-of-life scores in United States thyroid cancer survivors. <i>Surgery</i> , 2019, 166, 69-74.	1.0	60
12	Financial burden and quality of life among thyroid cancer survivors. <i>Surgery</i> , 2020, 167, 631-637.	1.0	50
13	Patient-Reported Outcomes in Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2016, 42, 253-263.	0.8	49
14	Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data. <i>Surgery</i> , 2018, 164, 986-992.	1.0	47
15	Development and Validation of 11 Symptom Indexes to Evaluate Response to Chemotherapy for Advanced Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 268-278.	2.3	40
16	Establishing clinically-relevant terms and severity thresholds for Patient-Reported Outcomes Measurement Information System® (PROMIS®) measures of physical function, cognitive function, and sleep disturbance in people with cancer using standard setting. <i>Quality of Life Research</i> , 2019, 28, 3355-3362.	1.5	40
17	Post-thyroidectomy neck appearance and impact on quality of life in thyroid cancer survivors. <i>Surgery</i> , 2019, 165, 1217-1221.	1.0	38
18	A Conceptual Model of the Experience of Dyspnea and Functional Limitations in Chronic Obstructive Pulmonary Disease. <i>Value in Health</i> , 2009, 12, 1018-1025.	0.1	37

#	ARTICLE	IF	CITATIONS
19	Development of a Conceptual Framework and Calibrated Item Banks to Measure Patient-Reported Dyspnea Severity and Related Functional Limitations. <i>Value in Health</i> , 2011, 14, 291-306.	0.1	33
20	Brief, Valid Measures of Dyspnea and Related Functional Limitations in Chronic Obstructive Pulmonary Disease (COPD). <i>Value in Health</i> , 2011, 14, 307-315.	0.1	29
21	Brief assessment of priority symptoms in hormone refractory prostate cancer: the FACT Advanced Prostate Symptom Index (FAPSI). <i>Health and Quality of Life Outcomes</i> , 2003, 1, 69.	1.0	26
22	A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores. <i>Quality of Life Research</i> , 2007, 16, 1615-1626.	1.5	24
23	Health-related quality of life in MEN1 patients compared with other chronic conditions and the United States general population. <i>Surgery</i> , 2018, 163, 205-211.	1.0	23
24	A Brief Symptom Index for Advanced Lung Cancer. <i>Clinical Lung Cancer</i> , 2012, 13, 14-23.	1.1	22
25	A patient-centered symptom monitoring and reporting system for children and young adults with cancer (SyMon-SAYS). <i>Pediatric Blood and Cancer</i> , 2015, 62, 1813-1818.	0.8	22
26	An innovative symptom monitoring tool for people with advanced lung cancer: a pilot demonstration. <i>The Journal of Supportive Oncology</i> , 2007, 5, 381-7.	2.3	22
27	Disease and treatment factors associated with lower quality of life scores in adults with multiple endocrine neoplasia type I. <i>Surgery</i> , 2017, 162, 1270-1277.	1.0	21
28	Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria. <i>PLoS ONE</i> , 2020, 15, e0237497.	1.1	21
29	Correlation of PROMIS scales and clinical measures among chronic obstructive pulmonary disease patients with and without exacerbations. <i>Quality of Life Research</i> , 2015, 24, 999-1009.	1.5	20
30	A method to create a standardized generic and condition-specific patient-reported outcome measure for patient care and healthcare improvement. <i>Quality of Life Research</i> , 2018, 27, 367-378.	1.5	19
31	PROMIS®: Standardizing the patient voice in health psychology research and practice.. <i>Health Psychology</i> , 2019, 38, 343-346.	1.3	19
32	Validation of the Functional Assessment of Cancer Therapy® Lung Symptom Index-12 (FLSI-12). <i>Lung Cancer</i> , 2007, 57, 339-347.	0.9	17
33	Financial burden is associated with worse health-related quality of life in adults with multiple endocrine neoplasia type 1. <i>Surgery</i> , 2017, 162, 1278-1285.	1.0	17
34	Development and Initial Validation of the PROMIS®-Plus-HF Profile Measure. <i>Circulation: Heart Failure</i> , 2019, 12, e005751.	1.6	17
35	Development and validation of the functional assessment of cancer therapy® antiangiogenesis subscale. <i>Cancer Medicine</i> , 2015, 4, 690-698.	1.3	11
36	Quality of life in multiple endocrine neoplasia type 2A compared with normative and disease populations. <i>Surgery</i> , 2018, 164, 546-552.	1.0	11

#	ARTICLE	IF	CITATIONS
37	Psychological Functioning in Patients With Chronic Obstructive Pulmonary Disease: A Preliminary Study of Relations With Smoking Status and Disease Impact. <i>Nicotine and Tobacco Research</i> , 2019, 21, 686-690.	1.4	11
38	Responsiveness of PROMIS® to change in chronic obstructive pulmonary disease. <i>Journal of Patient-Reported Outcomes</i> , 2019, 3, 65.	0.9	11
39	Serum adipokine levels and associations with patient-reported fatigue in systemic lupus erythematosus. <i>Rheumatology International</i> , 2018, 38, 1053-1061.	1.5	9
40	Methods and progress in assessing the quality of life effects of supportive care with erythropoietin therapy. <i>Current Opinion in Hematology</i> , 2002, 9, 234-240.	1.2	6
41	Validation of the Functional Assessment of Cancer Therapy–Leukemia instrument in patients with acute myeloid leukemia who are not candidates for intensive therapy. <i>Cancer</i> , 2020, 126, 3542-3551.	2.0	6
42	Assessment of Self-Management Treatment Needs Among COPD Helpline Callers. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2019, 16, 82-88.	0.7	5
43	<p>Assessing Preferences for Rare Disease Treatment: Qualitative Development of the Paroxysmal Nocturnal Hemoglobinuria Patient Preference Questionnaire (PNH-PPQ&A©)</p>. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 705-715.	0.8	5
44	Development of the Functional Assessment of Cancer Therapy-Carcinoid Syndrome Symptom Index. <i>Neuroendocrinology</i> , 2021, 111, 850-862.	1.2	4
45	Optimizing brief, focused assessment of priority symptoms and concerns in recurrent and/or metastatic squamous cell carcinoma of the head and neck: Content validation of the Functional Assessment of Cancer Therapy/National Comprehensive Cancer Network Head and Neck Symptom Index&A©10 (FHNSI&A©10). <i>Health Science Reports</i> . 2021, 4, e401.	0.6	2
46	Effects of patient-reported outcome assessment order. <i>Clinical Trials</i> , 2022, 19, 307-315.	0.7	2
47	The PROMIS&A©-Plus-Osteoarthritis of the Knee (OAK) profile measure integrates generic and condition-specific content to enhance relevance and efficiency. <i>Journal of Clinical Epidemiology</i> , 2021, 135, 158-169.	2.4	1
48	Optimizing brief, focused symptom assessment in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): The FHNSI-10.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18743-e18743.	0.8	1
49	Development and validation of the functional assessment of cancer therapy: Antiangiogenesis (FACT-AntiA).. <i>Journal of Clinical Oncology</i> , 2013, 31, e20527-e20527.	0.8	0
50	MON-558 Radioiodine Is Not Associated with Quality of Life Outcomes in Early Stage Thyroid Cancer Survivors, a Matched-Pair Analysis.. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.1	0
51	FACT physical wellbeing to independently predict overall survival in patients with acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2020, 38, 7532-7532.	0.8	0